Agency Business briefs: May 2013

Share this article:
Hensley Evans
Hensley Evans

Saatchi & Saatchi Wellness named ­Hensley Evans EVP director of analytics and strategy. Evans joins the Publicis shop from imc2 (née MEplus­YOU), where she was Chief Strategy Officer, having grown the pharma practice there from $3 million to $30 million by taking it national.

Omnicom said Tom Harrison, longtime head of its Diversified Agencies Services unit which houses the holding company's healthcare agencies, became chairman emeritus of the division April 1. Harrison, whose namesake agency Harrison & Star was acquired by Omnicom in 1992, has headed DAS, as it is known, for 16 years.

Ogilvy CommonHealth named Paul O'Neill to lead its Wellness Marketing consumer group. O'Neill joins the WPP shop from ICC Lowe, where he spent 11 years, most recently as chief growth officer for the global network.

Former Edelman Healthcare head Nancy Turett is launching WholeView, a healthcare leadership and communications consultancy.

ApotheCom Group named Eric Vollmuth CEO of Nitrogen. He joins from Ogilvy CommonHealth, where he was regional business driver, global brand ­management.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets